About this trial
Radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF) reduces left atrial (LA) volume post-ablation, a phenomenon termed reverse atrial remodeling, indicative of successful reversal of atrial cardiomyopathy progression. In contrast, pulse field ablation (PFA), a novel non-thermal technology, offers a promising efficacy and safety profile without inducing persistent atrial fibrosis. While RFCA-associated reverse atrial remodeling is well-documented, it remains uncertain whether PFA, operating on a non-thermal paradigm, also promotes this remodeling, which would enhance its physiological relevance in AF treatment. Additionally, RFCA studies show that LA wall thickness at the pulmonary vein (PV) antrum can predict PV reconnection and arrhythmia recurrence, but whether PFA affects LA thinning or enables similar predictions from post-treatment computed tomography (CT) scans is unknown. Moreover, epicardial adipose tissue (EAT), strongly linked to LA abnormalities and AF recurrence, can be quantified via CT, yet the impact of PFA on LA EAT remains unexplored. Finally, PFA's versatility, particularly in isolating the LA posterior wall (LAPW) in non-paroxysmal AF, raises questions about its effect on posterior wall thinning or EAT changes, factors associated with post-ablation recurrence
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age≥18 years at the time of AF ablation
AF ablation by pulse-field ablation (BOSTON SCIENTIFIC FARAPULSE) or by radiofrequency (any manufacturer) between 2020 and 2024
Paroxysmal or non-paroxysmal AF
Pre-ablation CT data available and of high quality
Disqualifiers
Low quality CT, non-homogeneous contrast agent perfusion
Post-ablation CT performed in another center
Patients in which pre- and post-ablation CTs do not share common phases
Patients who underwent ethanol infusion in the vein of Marshall
Trial population
All patients at Hôpital Pitié Salpêtrière meeting the study criteria
Trial design
Case-control
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Difference between baseline and post-ablation LA indexed volume (ml/cm^2)
Secondary outcomes
Difference between baseline and post-ablation mean wall thickness, mm
Difference between baseline and post-ablation Epicardial adipose tissue , mm^3
Difference between baseline and post-ablation left atrial appendage indexed volume, ml/cm^2
Difference between baseline and post-ablation left atrial appendage dimensions (long-axis, short-axis, ostium long-axis, ostium short-axis), mm
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Boston Scientific Corporation
Collaborator
This trial is not recruiting at the moment. You can still explore other options: